38 results
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:18pm
a “Pre-Phase-3 Briefing Package” to the FDA on July 28, 2022.
On August 22, 2022, the Company announced positive topline results from its XRX-OXY … . In advance of this meeting, XORTX submitted a “Pre-Phase-3 Briefing Package” to the FDA on July 28, 2022 and received responses from, and responded
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:15pm
) office, will review this initial application package and provide feedback and a decision, which is expected in December of this year. The EMA ODD
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:11pm
submitted a “Pre-Phase-3 Briefing Package” to the FDA on July 28, 2022.
On August 22, 2022, the Company announced positive topline results from its XRX-OXY … . In advance of this meeting, XORTX submitted a “Pre-Phase-3 Briefing Package” to the FDA on July 28, 2022 and received responses from, and responded
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:10pm
) office, will review this initial application package and provide feedback and a decision, which is expected in December of this year. The EMA ODD
424B5
ntrmmqu
29 Nov 23
Prospectus supplement for primary offering
9:57pm
6-K
EX-99.2
mfhzk ylofxtjarc
15 Nov 23
Condensed Interim Consolidated Financial Statements
9:30pm
6-K
EX-99.1
5191 xcr88bdbq
29 Aug 23
XORTX Submits Orphan Drug Designation Application to the European Medicines Agency (EMA) to Treat Progressive Kidney Disease
7:00am
6-K
EX-99.2
usjpgwta
30 May 23
Notice of Annual & Special Meeting of Shareholders
7:00am
6-K
EX-99.3
86q69log 9lp
3 Apr 23
Consolidated Financial Statements
6:05am
6-K
EX-99.2
gcma0p cfv
3 Apr 23
Consolidated Financial Statements
6:05am
424B3
od22c
14 Nov 22
Prospectus supplement
1:51pm
6-K
EX-99.2
mnr 5jgcx
14 Nov 22
Condensed Interim Consolidated Financial Statements
1:04pm
6-K
EX-99.1
6bdao
6 Oct 22
A.G.P./Alliance Global Partners
4:47pm
424B4
ljoc78723yjq6gtz2fd
5 Oct 22
Prospectus supplement with pricing info
5:24pm
POS AM
52g5olbc
29 Sep 22
Prospectus update (post-effective amendment)
9:49pm
F-1/A
wz1zu5vs1xo zplve6qd
21 Sep 22
Registration statement (foreign) (amended)
4:20pm